

Kirsten MÃ¼ller-Vahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5832605/publications.pdf>

Version: 2024-02-01

154
papers

6,539
citations

61977

43
h-index

85537

71
g-index

173
all docs

173
docs citations

173
times ranked

5107
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment failure in persistent tic disorders: an expert clinicians' consensus-based definition. <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 859-872.	4.7	10
2	European clinical guidelines for Tourette syndrome and other tic disorders"version 2.0. Part II: psychological interventions. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 403-423.	4.7	64
3	European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 377-382.	4.7	30
4	Stop that! It's not Tourette's but a new type of mass sociogenic illness. <i>Brain</i> , 2022, 145, 476-480.	7.6	54
5	European clinical guidelines for Tourette syndrome and other tic disorders"version 2.0. Part IV: deep brain stimulation. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 443-461.	4.7	26
6	European clinical guidelines for Tourette syndrome and other tic disorders"version 2.0. Part I: assessment. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 383-402.	4.7	35
7	Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. <i>Neurologia i Neurochirurgia Polska</i> , 2022, 56, 28-38.	1.2	14
8	European clinical guidelines for Tourette syndrome and other tic disorders"version 2.0. Part III: pharmacological treatment. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 425-441.	4.7	64
9	Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2022, 55, 148-156.	3.3	11
10	ONLINE-TICS: Internet-Delivered Behavioral Treatment for Patients with Chronic Tic Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 250.	2.4	11
11	Reply: A call for caution: "stop that" sentiments threaten tic research, healthcare and advocacy progress. <i>Brain</i> , 2022, 145, e21-e23.	7.6	3
12	Premonitory Urges Reconsidered: Urge Location Corresponds to Tic Location in Patients With Primary Tic Disorders. <i>Journal of Movement Disorders</i> , 2022, 15, 43-52.	1.3	14
13	Lack of Association of Group A Streptococcal Infections and Onset of Tics. <i>Neurology</i> , 2022, 98, .	1.1	16
14	Altered performance monitoring in Tourette Syndrome: an MEG investigation. <i>Scientific Reports</i> , 2022, 12, 8300.	3.3	1
15	Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome. <i>International Review of Movement Disorders</i> , 2022, , .	0.1	0
16	Developing the Premonitory Urges for Tic Disorders Scale"Revised (PUTS"R). <i>Journal of Neuropsychology</i> , 2021, 15, 129-142.	1.4	9
17	Two Decades of the International Association for Cannabinoid Medicines: 20 Years of Supporting Research and Activities Toward the Medicinal Use of Cannabis and Cannabinoids. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 82-87.	2.9	2
18	Synaptic processes and immune-related pathways implicated in Tourette syndrome. <i>Translational Psychiatry</i> , 2021, 11, 56.	4.8	31

#	ARTICLE	IF	CITATIONS
19	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. <i>Neurology</i> , 2021, 96, e1680-e1693.	1.1	30
20	Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. <i>Pharmaceutical Statistics</i> , 2021, 20, 675-691.	1.3	4
21	The Phenomenon of Exquisite Motor Control in Tic Disorders and its Pathophysiological Implications. <i>Movement Disorders</i> , 2021, 36, 1308-1315.	3.9	7
22	Case in Context: Tourette Syndrome. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 88-91.	2.9	3
23	Challenges in the Diagnosis and Assessment in Patients with Tourette Syndrome and Comorbid Obsessive-Compulsive Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1253-1266.	2.2	14
24	Elevated Free Phosphatidylcholine Levels in Cerebrospinal Fluid Distinguish Bacterial from Viral CNS Infections. <i>Cells</i> , 2021, 10, 1115.	4.1	9
25	Randomized double-blind sham-controlled trial of thalamic versus GPi stimulation in patients with severe medically refractory Gilles de la Tourette syndrome. <i>Brain Stimulation</i> , 2021, 14, 662-675.	1.6	16
26	Is Tourette syndrome a rare disease?. <i>F1000Research</i> , 2021, 10, 434.	1.6	2
27	Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study. <i>Movement Disorders</i> , 2021, 36, 2413-2418.	3.9	29
28	Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. <i>Journal of Cannabis Research</i> , 2021, 3, 22.	3.2	68
29	Cannabis Improves Stuttering: Case Report and Interview with the Patient. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 372-380.	2.9	0
30	Validation of the Rage Attack Questionnaire-Revised (RAQ-R) in a Mixed Psychiatric Population. <i>Frontiers in Psychiatry</i> , 2021, 12, 724802.	2.6	0
31	Yale Global Tic Severity Scale (YGTSS): Psychometric Quality of the Gold Standard for Tic Assessment Based on the Large-Scale EMTICS Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 626459.	2.6	31
32	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 43.	2.0	8
33	Mind the Difference Between Primary Tics and Functional Tic-like Behaviors. <i>Movement Disorders</i> , 2021, 36, 2716-2718.	3.9	9
34	Phosphatidylcholine PC ae C44:6 in cerebrospinal fluid is a sensitive biomarker for bacterial meningitis. <i>Journal of Translational Medicine</i> , 2020, 18, 9.	4.4	12
35	Neural correlates of performance monitoring in adult patients with Gilles de la Tourette syndrome: A study of event-related potentials. <i>Clinical Neurophysiology</i> , 2020, 131, 597-608.	1.5	4
36	The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 575826.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Cannabis Improves Obsessive-Compulsive Disorder – Case Report and Review of the Literature. <i>Frontiers in Psychiatry</i> , 2020, 11, 681.	2.6	17
38	Intravenous Immunoglobulin Treatment Did Not Improve Tics in a Patient With Gilles de la Tourette Syndrome and Intrathecal Antibody Synthesis. <i>Frontiers in Neurology</i> , 2020, 11, 110.	2.4	4
39	Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. <i>Neuropsychopharmacology</i> , 2020, 45, 1323-1329.	5.4	41
40	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	4.7	36
41	Deep brain stimulation in Tourette syndrome: the known and the unknown. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1076-1077.	1.9	9
42	Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome. <i>Medical Cannabis and Cannabinoids</i> , 2019, 2, 60-64.	3.3	9
43	Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study. <i>Frontiers in Neurology</i> , 2019, 10, 732.	2.4	17
44	Possible Role of the Endocannabinoid System in Tourette Syndrome. , 2019, , .		4
45	Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 265-274.	2.9	34
46	The spectrum of involuntary vocalizations in humans: A video atlas. <i>Movement Disorders</i> , 2019, 34, 1774-1791.	3.9	24
47	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 665-669.	4.1	15
48	Tic disorders revisited: introduction of the term “œtic spectrum disorders”. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1129-1135.	4.7	48
49	Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. <i>Scientific Reports</i> , 2019, 9, 972.	3.3	16
50	Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous System Infections. <i>Journal of Infectious Diseases</i> , 2019, 220, 127-138.	4.0	37
51	A peek into premonitory urges in Tourette syndrome: Temporal evolution of neurophysiological oscillatory signatures. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 153-158.	2.2	10
52	Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019, 92, 896-906.	1.1	270
53	Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019, 92, 907-915.	1.1	138
54	Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. <i>American Journal of Psychiatry</i> , 2019, 176, 217-227.	7.2	242

#	ARTICLE	IF	CITATIONS
55	Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. <i>Depression and Anxiety</i> , 2019, 36, 198-212.	4.1	63
56	Cannabinoids in functional tic-like movements. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 179-181.	2.2	4
57	The Rage Attack Questionnaire-Revised (RAQ-R): Assessing Rage Attacks in Adults With Tourette Syndrome. <i>Frontiers in Psychiatry</i> , 2019, 10, 956.	2.6	17
58	Position-Dependent Dysfunction of Deep Brain Stimulation in Tourette Syndrome: Diagnostic Clues. Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	0
59	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 301-316.	3.2	23
60	Intact automatic motor inhibition in patients with tourette syndrome. <i>Movement Disorders</i> , 2018, 33, 1800-1804.	3.9	12
61	De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis. <i>Cell Reports</i> , 2018, 24, 3441-3454.e12.	6.4	91
62	Pallidal and thalamic neural oscillatory patterns in tourette's syndrome. <i>Annals of Neurology</i> , 2018, 84, 505-514.	5.3	65
63	Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. <i>Journal of Psychiatric Research</i> , 2017, 86, 1-8.	3.1	30
64	The human globus pallidus internus is sensitive to rewards " Evidence from intracerebral recordings. <i>Brain Stimulation</i> , 2017, 10, 657-663.	1.6	17
65	Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. <i>Neuron</i> , 2017, 94, 1101-1111.e7.	8.1	137
66	Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. <i>Brain</i> , 2017, 140, 218-234.	7.6	68
67	Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. <i>Developmental Cognitive Neuroscience</i> , 2017, 27, 78-90.	4.0	29
68	Editorial: The Neurobiology and Genetics of Gilles de la Tourette Syndrome: New Avenues through Large-Scale Collaborative Projects. <i>Frontiers in Psychiatry</i> , 2017, 8, 197.	2.6	2
69	Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1739.	4.1	29
70	Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. <i>Brain Sciences</i> , 2017, 7, 47.	2.3	35
71	New Insights into Clinical Characteristics of Gilles de la Tourette Syndrome: Findings in 1032 Patients from a Single German Center. <i>Frontiers in Neuroscience</i> , 2016, 10, 415.	2.8	104
72	Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. <i>Frontiers in Neuroscience</i> , 2016, 10, 416.	2.8	36

#	ARTICLE	IF	CITATIONS
73	Effect of Deep Brain Stimulation on Regional Cerebral Blood Flow in Patients with Medically Refractory Tourette Syndrome. <i>Frontiers in Psychiatry</i> , 2016, 7, 118.	2.6	18
74	The ONLINE-TICS Study Protocol: A Randomized Observer-Blind Clinical Trial to Demonstrate the Efficacy and Safety of Internet-Delivered Behavioral Treatment for Adults with Chronic Tic Disorders. <i>Frontiers in Psychiatry</i> , 2016, 7, 119.	2.6	31
75	TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. <i>Frontiers in Neuroscience</i> , 2016, 10, 384.	2.8	21
76	Increased beta rhythm as an indicator of inhibitory mechanisms in tourette syndrome. <i>Movement Disorders</i> , 2016, 31, 384-392.	3.9	18
77	Current and Future Needs and Applications for Cannabis. <i>Critical Reviews in Plant Sciences</i> , 2016, 35, 425-426.	5.7	8
78	Medicinal Uses of Marijuana and Cannabinoids. <i>Critical Reviews in Plant Sciences</i> , 2016, 35, 378-405.	5.7	46
79	â€œI swear it is Tourette's!â€ On functional coprolalia and other tic-like vocalizations. <i>Psychiatry Research</i> , 2016, 246, 821-826.	3.3	56
80	Association of AADAC Deletion and Gilles de la Tourette Syndrome in a Large European Cohort. <i>Biological Psychiatry</i> , 2016, 79, 383-391.	1.3	41
81	Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. <i>Molecular Brain</i> , 2015, 8, 62.	2.6	10
82	Blocking Phenomena in Gilles de la Tourette Syndrome. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 438-439.	1.5	11
83	Cannabinoids and the Tourette syndrome. , 2015, , 227-245.		2
84	Comparative characterization of single cell activity in the globus pallidus internus of patients with dystonia or Tourette syndrome. <i>Journal of Neural Transmission</i> , 2015, 122, 687-699.	2.8	36
85	Severe Self-Injurious Behavior With Teeth Extraction in a Boy With Tourette Syndrome. <i>Pediatric Neurology</i> , 2015, 52, e5.	2.1	3
86	Patients with Gilles de la Tourette syndrome have widespread personality differences. <i>Psychiatry Research</i> , 2015, 228, 765-773.	3.3	16
87	Narcissistic vulnerability is a common cause for depression in patients with Gilles de la Tourette syndrome. <i>Psychiatry Research</i> , 2015, 230, 695-703.	3.3	8
88	Obsessive-compulsive disorder is a heterogeneous disorder: evidence from diffusion tensor imaging and magnetization transfer imaging. <i>BMC Psychiatry</i> , 2015, 15, 135.	2.6	28
89	Costs of control: decreased motor cortex engagement during a Go/NoGo task in Touretteâ€™s syndrome. <i>Brain</i> , 2014, 137, 122-136.	7.6	72
90	Can Tics be Performed Convincingly by an Actor?. <i>Behavioural Neurology</i> , 2014, 2014, 1-3.	2.1	1

#	ARTICLE	IF	CITATIONS
91	Altered intrahemispheric structural connectivity in Gilles de la Tourette syndrome. <i>NeuroImage: Clinical</i> , 2014, 4, 174-181.	2.7	60
92	Tics are caused by alterations in prefrontal areas, thalamus and putamen, while changes in the cingulate gyrus reflect secondary compensatory mechanisms. <i>BMC Neuroscience</i> , 2014, 15, 6.	1.9	53
93	Tourette patients' misbelief of a tic rebound is due to overall difficulties in reliable tic rating. <i>Journal of Psychosomatic Research</i> , 2014, 76, 472-476.	2.6	44
94	The Medicinal Use of Cannabis and Cannabinoids – An International Cross-Sectional Survey on Administration Forms. <i>Journal of Psychoactive Drugs</i> , 2013, 45, 199-210.	1.7	189
95	Surgical treatment of Tourette syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1178-1185.	6.1	42
96	Impact of placebo assignment in clinical trials of tic disorders. <i>Movement Disorders</i> , 2013, 28, 1288-1292.	3.9	35
97	Treatment of Tourette Syndrome with Cannabinoids. <i>Behavioural Neurology</i> , 2013, 27, 119-124.	2.1	65
98	Treatment of Tourette syndrome with cannabinoids. <i>Behavioural Neurology</i> , 2013, 27, 119-24.	2.1	39
99	Cannabis Therapy. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 144.	0.9	1
100	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 175.	0.9	0
101	Aripiprazole for the Treatment of Tourette Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 548-550.	1.4	34
102	The Therapeutic Potential of Cannabis and Cannabinoids. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 495-501.	0.9	227
103	Monolingual coprolalia in bilingual patients with Tourette syndrome. <i>Movement Disorders</i> , 2012, 27, 1468-1468.	3.9	2
104	Increased sensory feedback in Tourette syndrome. <i>NeuroImage</i> , 2012, 63, 119-125.	4.2	39
105	Tourette Syndrome and Other Tic Disorders in Childhood, Adolescence and Adulthood. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 821-288.	0.9	52
106	Lateral frontal cortex volume reduction in Tourette syndrome revealed by VBM. <i>BMC Neuroscience</i> , 2012, 13, 17.	1.9	37
107	Oligoclonal bands in cerebrospinal fluid in patients with Tourette's syndrome. <i>Movement Disorders</i> , 2011, 26, 343-346.	3.9	22
108	European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 209-217.	4.7	147

#	ARTICLE	IF	CITATIONS
109	Does Tourette syndrome prevent tardive dyskinesia?. <i>Movement Disorders</i> , 2011, 26, 2442-2443.	3.9	37
110	Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome. <i>Movement Disorders</i> , 2011, 26, 2447-2447.	3.9	17
111	Cost of illness in patients with Gilles de la Tourette's syndrome. <i>Journal of Neurology</i> , 2010, 257, 1055-1061.	3.6	26
112	Health-related quality of life in patients with Gilles de la Tourette's syndrome. <i>Movement Disorders</i> , 2010, 25, 309-314.	3.9	91
113	Imitation in patients with Gilles de la Tourette syndrome: A behavioral study. <i>Movement Disorders</i> , 2010, 25, 991-999.	3.9	26
114	Is it a tic? Twenty seconds to make a diagnosis. <i>Movement Disorders</i> , 2010, 25, 1106-1108.	3.9	43
115	Interhemispheric motor networks are abnormal in patients with Gilles de la Tourette syndrome. <i>Movement Disorders</i> , 2010, 25, 2828-2837.	3.9	42
116	Structural changes in the somatosensory system correlate with tic severity in Gilles de la Tourette syndrome. <i>Brain</i> , 2009, 132, 765-777.	7.6	136
117	Prefrontal and anterior cingulate cortex abnormalities in Tourette Syndrome: evidence from voxel-based morphometry and magnetization transfer imaging. <i>BMC Neuroscience</i> , 2009, 10, 47.	1.9	134
118	Coprophobia in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 218-227.	2.1	131
119	Tourette's Syndrome. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 1, 397-410.	1.7	5
120	Immunophenotyping in Tourette syndrome: a pilot study. <i>European Journal of Neurology</i> , 2008, 15, 749-753.	3.3	23
121	The influence of different food and drink on tics in Tourette syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2008, 97, 442-446.	1.5	27
122	Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1037-1048.	2.8	102
123	The Pathophysiological Role of the Serotonergic System in Tourette Syndrome. <i>Current Psychiatry Reviews</i> , 2007, 3, 271-276.	0.9	0
124	Role of the novel tryptophan hydroxylase-2 gene in Tourette syndrome. <i>Molecular Psychiatry</i> , 2007, 12, 617-619.	7.9	38
125	Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and 123I-β-CIT-SPECT. <i>Journal of Neurology</i> , 2007, 254, 1081-1088.	3.6	53
126	Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 249-256.	1.8	18

#	ARTICLE	IF	CITATIONS
127	Serotonin transporter binding in Tourette Syndrome. <i>Neuroscience Letters</i> , 2005, 385, 120-125.	2.1	70
128	Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. , 2004, 127B, 97-103.		41
129	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after $\hat{1}^9$ -tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. <i>Biological Psychiatry</i> , 2004, 55, 904-915.	1.3	51
130	Cannabinoids reduce symptoms of Tourette's syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1717-1725.	1.8	59
131	Treatment of Tourette Syndrome with Delta-9-Tetrahydrocannabinol ($\hat{1}^9$ -THC): No Influence on Neuropsychological Performance. <i>Neuropsychopharmacology</i> , 2003, 28, 384-388.	5.4	75
132	Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 459-465.	2.2	216
133	Disturbed Monitoring and Response Inhibition in patients with Gilles De La Tourette Syndrome and Co-Morbid Obsessive Compulsive Disorder. <i>Behavioural Neurology</i> , 2003, 14, 29-37.	2.1	59
134	Tourette Syndrome and Obsessive-Compulsive Disorder: Event-Related Brain Potentials Show Similar Mechanisms of Frontal Inhibition but Dissimilar Target Evaluation Processes. <i>Behavioural Neurology</i> , 2003, 14, 9-17.	2.1	35
135	Combined Treatment of Tourette Syndrome with $\hat{1}^9$ -THC and Dopamine Receptor Antagonists. <i>Journal of Cannabis Therapeutics</i> , 2002, 2, 145-154.	1.1	12
136	Treatment of Tourette's Syndrome with $\hat{1}^9$ -Tetrahydrocannabinol (THC): A Randomized Crossover Trial. <i>Pharmacopsychiatry</i> , 2002, 35, 57-61.	3.3	210
137	The treatment of Tourette's syndrome: current opinions. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 899-914.	1.8	26
138	Excessive action monitoring in Tourette syndrome. <i>Journal of Neurology</i> , 2002, 249, 961-966.	3.6	70
139	Electrophysiological measures and dual-task performance in Tourette syndrome indicate deficient divided attention mechanisms. <i>European Journal of Neurology</i> , 2001, 8, 253-260.	3.3	36
140	Altered inhibition of motor responses in Tourette Syndrome and Obsessive-Compulsive Disorder. <i>Acta Neurologica Scandinavica</i> , 2001, 104, 36-43.	2.1	79
141	Influence of Treatment of Tourette Syndrome with $\hat{1}^9$ -Tetrahydrocannabinol ($\hat{1}^9$ -THC) on Neuropsychological Performance. <i>Pharmacopsychiatry</i> , 2001, 34, 19-24.	3.3	53
142	Mitochondriopathy, blepharospasm, and treatment with botulinum toxin. , 2000, 23, 647-648.		13
143	Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 165-171.	2.1	55
144	Dopamine transporter binding in Gilles de la Tourette syndrome. <i>Journal of Neurology</i> , 2000, 247, 514-520.	3.6	82

#	ARTICLE	IF	CITATIONS
145	Cannabis in Movement Disorders. <i>Complementary Medicine Research</i> , 1999, 6, 23-27.	1.2	54
146	Effects of Fentanyl and Low Doses of Alcohol on Neuropsychological Performance in Healthy Subjects. <i>Neuropsychobiology</i> , 1999, 39, 38-43.	1.9	21
147	Nabilone increases choreatic movements in Huntington's disease. <i>Movement Disorders</i> , 1999, 14, 1038-1040.	3.9	62
148	Effects of acamprosate on memory in healthy young subjects.. <i>Journal of Studies on Alcohol and Drugs</i> , 1999, 60, 172-175.	2.3	23
149	Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. <i>American Journal of Psychiatry</i> , 1999, 156, 495.	7.2	23
150	Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. <i>Acta Psychiatrica Scandinavica</i> , 1998, 98, 502-506.	4.5	119
151	Alcohol withdrawal and Tourette's syndrome. <i>Neurology</i> , 1997, 48, 1478-1479.	1.1	10
152	Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette Syndrome. <i>European Journal of Neurology</i> , 1997, 4, 152-161.	3.3	24
153	Clarity on Cannabinoid-Based Products in Medicine. <i>European Medical Journal Neurology</i> , 0, , .	0.0	1
154	Is Tourette syndrome a rare condition?. <i>F1000Research</i> , 0, 10, 434.	1.6	3